A New Phase for Chinese Pharmaceuticals
There's a shift in the pharma world, with Fosun International leading the charge. Chinese innovative drugs are stepping onto the global stage, thanks to efforts like those of Chen Qiyu, Co-CEO of Fosun. At the Sustainability Global Leaders Conference 2026, he spoke about transforming Chinese market players into worldwide contributors. It's not just talk; the figures are big—USD 136 billion in out-licensing deals in 2025, surpassing USD 100 billion in the first half of 2026. This isn't small-time stuff.
The Case of Fosun's Breakthroughs
Fosun's been hammering away in the pharmaceuticals and healthcare sector since they ventured into PCR tech back in 1993. These guys aren't resting on their laurels. Take artesunate, a malaria lifesaver, as a prime example. Fosun didn't just stop at acquiring Guilin Pharma; they invested in R&D, improving manufacturing and quality systems to get this drug out to the world.
"The value of Chinese innovation lies not only in developing world-class products, but also in making them accessible to more people worldwide," Chen Qiyu shared.
Affordability and Reliability: The Core
Affordability and reliability are the crown jewels here. Fosun's HANQUYOU biosimilar slashed costs compared to its pricey original drug counterpart. It means more patients can afford the treatment they deserve. But affordability isn't the endgame—it's quality that people can trust that really counts.
- Affordable Pricing: Fosun set new benchmarks with HANQUYOU, cutting annual costs significantly.
- Quality Standards: Rigorous international testing ensures reliability and safety.
Meeting Challenges Head-On
Chinese drug companies can't just rinse and repeat what's been done by the pharmaceutical giants across the pond. They've got to innovate on lean budgets and deliver big. This means harnessing tech platforms, AI tools, and advanced manufacturing to keep costs down while maintaining quality. That's Fosun's playbook right now: get it done without breaking the bank.
Bigger Horizons Through Innovation
An intriguing part of Fosun's tale is their focus on building a sustainable innovation machine. Moving beyond single breakthroughs, they're ratcheting up efforts to establish an open, globally integrated R&D network. This shift is crucial for Fosun, allowing them to churn out a steady stream of new drugs.
AI: The New Pharma Wild Card
AI's come a long way. For Fosun, it's morphing into a key driver in their pharmaceutical endeavors. Their PharmAID® platform is a case in point, supporting AI-powered drug development across the entire lifecycle—from early R&D stages to commercialization. They’ve got over 25 high-value AI projects rolling out, proving Chen’s point that AI could reshape pharma innovation.
"AI is not merely a tool for improving efficiency; it has the potential to become a transformative force that reshapes the future of pharmaceutical innovation," Chen Qiyu elaborated.
The Road Ahead for Fosun
Fosun's planning to plant deeper global roots as a 'C-MNC', or China-Multinational Corporation. They've got their eyes set on blending Chinese innovation strengths with global collaboration, making affordable drugs more accessible worldwide. And they're not doing this just for profit; they're doing it to genuinely better lives around the globe.
Chen stressed, "Science determines how far innovation can go, but its true value is measured by the lives it improves." It's a profound insight that suggests Fosun's efforts aren't just about getting ahead; they’re about pushing the human condition forward.
Fosun's commitment to affordability, reliability, and innovation isn't just a manifesto—it's what they're banking on to drive their growth and impact globally. With ambitions set on the world stage, and AI giving them an edge, Fosun might really be reshaping the future of pharmaceuticals.
